JP2024504378A - トリアジン化合物ならびにこれを作製する方法および使用する方法 - Google Patents

トリアジン化合物ならびにこれを作製する方法および使用する方法 Download PDF

Info

Publication number
JP2024504378A
JP2024504378A JP2023544345A JP2023544345A JP2024504378A JP 2024504378 A JP2024504378 A JP 2024504378A JP 2023544345 A JP2023544345 A JP 2023544345A JP 2023544345 A JP2023544345 A JP 2023544345A JP 2024504378 A JP2024504378 A JP 2024504378A
Authority
JP
Japan
Prior art keywords
group
optionally substituted
compound according
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504378A5 (cg-RX-API-DMAC7.html
Inventor
イリオポウロス,ディミトリオス
ジー. ホー,デイヴィッド
カラギアニディス,ヨルダニス
グエン,ピティ
ハルキア,ディミトラ
Original Assignee
アトス セラピューティクス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトス セラピューティクス,インコーポレイテッド filed Critical アトス セラピューティクス,インコーポレイテッド
Publication of JP2024504378A publication Critical patent/JP2024504378A/ja
Publication of JP2024504378A5 publication Critical patent/JP2024504378A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023544345A 2021-01-25 2022-01-24 トリアジン化合物ならびにこれを作製する方法および使用する方法 Pending JP2024504378A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141316P 2021-01-25 2021-01-25
US63/141,316 2021-01-25
PCT/US2022/070321 WO2022159981A1 (en) 2021-01-25 2022-01-24 Triazine compounds and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2024504378A true JP2024504378A (ja) 2024-01-31
JP2024504378A5 JP2024504378A5 (cg-RX-API-DMAC7.html) 2025-01-30

Family

ID=82549984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544345A Pending JP2024504378A (ja) 2021-01-25 2022-01-24 トリアジン化合物ならびにこれを作製する方法および使用する方法

Country Status (4)

Country Link
US (1) US20250188062A1 (cg-RX-API-DMAC7.html)
EP (1) EP4281447A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024504378A (cg-RX-API-DMAC7.html)
WO (1) WO2022159981A1 (cg-RX-API-DMAC7.html)

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620528A1 (de) * 1965-12-31 1970-06-11 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen basisch substituierten s-Triazinen
JPS6455557A (en) * 1987-08-26 1989-03-02 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
US5099019A (en) * 1985-09-12 1992-03-24 Upjohn Company Amines useful in producing pharmaceutically active CNS compounds
JPH069584A (ja) * 1990-04-11 1994-01-18 Ministero Dell Univ E Della Ric Scient & Tecnol トリアジン化合物とリンの酸素化酸との塩
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
WO2008154798A1 (fr) * 2007-06-15 2008-12-24 Peking University Composés photosensibles de la n,n-dialkylamidophényl-dipyrazolyl triazine, leurs complexes d'europium et leurs procédés de préparation
WO2009035671A1 (en) * 2007-09-12 2009-03-19 Janssen Pharmaceutica N.V. Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor
CN101838476A (zh) * 2009-03-18 2010-09-22 北京大学 一类有机荧光染料化合物及其合成方法与应用
JP2010534677A (ja) * 2007-07-25 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー トリアジンキナーゼ阻害剤
WO2011005119A1 (en) * 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2011522802A (ja) * 2008-05-23 2011-08-04 ワイス・エルエルシー PI3キナーゼおよびmTOR阻害剤としてのトリアジン化合物
WO2012020762A1 (ja) * 2010-08-10 2012-02-16 アステラス製薬株式会社 へテロ環化合物
JP2012508223A (ja) * 2008-11-10 2012-04-05 ユニバーシティ オブ バーゼル トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用
WO2012052390A1 (en) * 2010-10-19 2012-04-26 Glaxo Group Limited N-2-(2-pyridinyl)-4-pyrimidinyl-beta-alanine derivatives as inhibitors of histone demethylase jmjd3
WO2012101654A2 (en) * 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds
CN106608869A (zh) * 2015-10-27 2017-05-03 中国科学院上海药物研究所 一类组蛋白去甲基化酶jmjd3抑制剂及其制备方法和用途
CN108727369A (zh) * 2017-04-25 2018-11-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors
WO2020219963A1 (en) * 2019-04-26 2020-10-29 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620528A1 (de) * 1965-12-31 1970-06-11 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen basisch substituierten s-Triazinen
US5099019A (en) * 1985-09-12 1992-03-24 Upjohn Company Amines useful in producing pharmaceutically active CNS compounds
JPS6455557A (en) * 1987-08-26 1989-03-02 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
JPH069584A (ja) * 1990-04-11 1994-01-18 Ministero Dell Univ E Della Ric Scient & Tecnol トリアジン化合物とリンの酸素化酸との塩
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
WO2008154798A1 (fr) * 2007-06-15 2008-12-24 Peking University Composés photosensibles de la n,n-dialkylamidophényl-dipyrazolyl triazine, leurs complexes d'europium et leurs procédés de préparation
JP2010534677A (ja) * 2007-07-25 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー トリアジンキナーゼ阻害剤
WO2009035671A1 (en) * 2007-09-12 2009-03-19 Janssen Pharmaceutica N.V. Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine h4 receptor
JP2011522802A (ja) * 2008-05-23 2011-08-04 ワイス・エルエルシー PI3キナーゼおよびmTOR阻害剤としてのトリアジン化合物
JP2012508223A (ja) * 2008-11-10 2012-04-05 ユニバーシティ オブ バーゼル トリアジン、ピリミジン、及びピリジン類似体、並びに、治療薬及び診断プローブとしてのそれらの使用
CN101838476A (zh) * 2009-03-18 2010-09-22 北京大学 一类有机荧光染料化合物及其合成方法与应用
WO2011005119A1 (en) * 2009-07-07 2011-01-13 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2012020762A1 (ja) * 2010-08-10 2012-02-16 アステラス製薬株式会社 へテロ環化合物
WO2012052390A1 (en) * 2010-10-19 2012-04-26 Glaxo Group Limited N-2-(2-pyridinyl)-4-pyrimidinyl-beta-alanine derivatives as inhibitors of histone demethylase jmjd3
WO2012101654A2 (en) * 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds
CN106608869A (zh) * 2015-10-27 2017-05-03 中国科学院上海药物研究所 一类组蛋白去甲基化酶jmjd3抑制剂及其制备方法和用途
CN108727369A (zh) * 2017-04-25 2018-11-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors
WO2020219963A1 (en) * 2019-04-26 2020-10-29 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"CAS登録番号1505406-05-2", REGISTRY(STN)[ONLINE], JPN7025005195, 27 December 2013 (2013-12-27), ISSN: 0005743997 *
"CAS登録番号1533644-95-9", REGISTRY(STN)[ONLINE], JPN7025005191, 30 January 2014 (2014-01-30), ISSN: 0005743986 *
"CAS登録番号1535979-13-5, 1502134-34-0, 1323537-59-2", REGISTRY(STN)[ONLINE], JPN7025005193, 3 February 2014 (2014-02-03), ISSN: 0005743988 *
"CAS登録番号1542514-55-5, 1540874-06-3, 1510581-42-6, 1493599-99-7", REGISTRY(STN)[ONLINE], JPN7025005192, 13 February 2014 (2014-02-13), ISSN: 0005743987 *
"CAS登録番号1598418-79-1, 1503213-47-5, 1503001-13-5, 1501409-47-7, 1501076-41-0, 1500608-37-6", REGISTRY(STN)[ONLINE], JPN7025005194, 6 May 2014 (2014-05-06), ISSN: 0005743996 *
"CAS登録番号1958765-82-6", REGISTRY(STN)[ONLINE], JPN7025005190, 24 July 2016 (2016-07-24), ISSN: 0005743985 *
C. DI NICOLA ET AL.: "Synthesis, characterization, crystal structure and preliminary reactivity behaviour of new heteropol", DALTON TRANSACTIONS, vol. 40, no. 18, JPN6025049394, 2011, pages 4941, ISSN: 0005743991 *
IZAR CAPEL BERDIELL ET AL.: "Heterometallic Coordination Polymer Gels Supported by 2,4,6-Tris(pyrazol-1-yl)-1,3,5-triazine", ACS OMEGA, vol. 3, no. 12, JPN6025049392, 27 December 2018 (2018-12-27), pages 18466 - 18474, ISSN: 0005743989 *
IZAR CAPEL BERDIELL ET AL.: "Iron(II) Complexes of 2,4-Dipyrazolyl-1,3,5-triazine Derivatives-The Influence of Ligand Geometry on", INORGANIC CHEMISTRY, vol. 56, no. 15, JPN6025049393, 12 July 2017 (2017-07-12), pages 8817 - 8828, ISSN: 0005743990 *
JIANPING HU ET AL.: "Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, no. 3, JPN6025049396, February 2016 (2016-02-01), pages 721 - 725, ISSN: 0005743993 *
M. PILAR CARRANZA ET AL.: "Experimental and theoretical evidence of unsupported Ag-Ag interactions in complexes with triazine-b", NEW JOURNAL OF CHEMISTRY, vol. 37, no. 10, JPN6025049395, 2013, pages 3183, ISSN: 0005743992 *
TOSHIYUKI MATSUNO ET AL.: "Synthesis and Aromatase-Inhibitory Activity of Imidazolyl-1,3,5-triazine Derivatives.", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 45, no. 2, JPN6025049390, 1997, pages 291 - 296, ISSN: 0005743983 *
TSUTOMU IRIKURA ET AL.: "New s-triazine derivatives as depressants for reticuloendothelial hyperfunction induced by bacterial", JOURNAL OF MEDICINAL CHEMISTRY, vol. 13, no. 6, JPN6025049397, November 1970 (1970-11-01), pages 1081 - 1089, ISSN: 0005743994 *
WEI CHEN ET AL.: "Synthesis, characterization and preliminary reactivity behaviors with transitional metals of a new p", JOURNAL OF MOLECULAR STRUCTURE, vol. 1068, JPN6025049389, June 2014 (2014-06-01), pages 237 - 244, ISSN: 0005869013 *
XIAO-MENG WANG ET AL.: "Design, synthesis and antiproliferative activity evaluation of m-(4-morpholinyl-1,3,5-triazin-2-yl)b", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, no. 8, JPN6025049398, April 2015 (2015-04-01), pages 1730 - 1735, ISSN: 0005743995 *
ZHI‐WEI MAO ET AL.: "Design and Development of Novel 4‐(4‐(1H‐Tetrazol‐5‐yl)‐1H‐pyrazol‐1‐yl)‐6‐morpholino‐N", ARCHIV DER PHARMAZIE, vol. 349, no. 4, JPN6025049391, 2 March 2016 (2016-03-02), pages 268 - 276, ISSN: 0005743984 *

Also Published As

Publication number Publication date
WO2022159981A1 (en) 2022-07-28
EP4281447A4 (en) 2025-06-04
EP4281447A1 (en) 2023-11-29
US20250188062A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
US10954243B2 (en) Substituted heterocyclic inhibitors of PTPN11
US20230091225A1 (en) Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof
US20230011726A1 (en) KRAS mutant protein inhibitors
RU2622104C2 (ru) Макроциклические ингибиторы киназы lrrk2
JP7369458B2 (ja) ヒストンデアセチラーゼ6阻害剤としての1,2,4-オキサジアゾール誘導体
KR101964251B1 (ko) 약학적 화합물
US20200317686A1 (en) Compounds targeting prmt5
WO2023131167A1 (zh) 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
TWI669300B (zh) 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
US11136338B2 (en) Fused thiazolopyrimidine derivatives as MNKs inhibitors
US11008318B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
US20250214980A1 (en) Multicyclic compounds
EP3510030B1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
CN117229263A (zh) 一种抑制或降解Bcl6的化合物及其在医药中的应用
US20250188062A1 (en) Triazine compounds and methods of making and using the same
WO2023143384A1 (zh) 一种抑制或降解hpk1激酶的化合物及其在医药中的用途
JP2024511012A (ja) キナーゼ関連疾患の処置のための小分子
US20250042850A1 (en) Pharmaceutical compounds and methods of making and using the same
KR20250161024A (ko) 바닌-1 억제제
RU2797613C2 (ru) Производные 1,2,4-оксадиазола в качестве ингибиторов гистондезацетилазы 6
CN121816354A (zh) 用于治疗自身免疫性疾病的小分子
CN118891252A (zh) 多环化合物
HK40093207A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
HK40065647A (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
CN121591736A (zh) Hpk1抑制剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260526